sponsored
PatientsVille.com Logo

PatientsVille

Cefoperazone/sulbactam Medical Research Studies

Up-to-date List of Cefoperazone/sulbactam Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Cefoperazone/sulbactam Medical Research Studies

Rank Status Study
1 Recruiting Air Pollution, Inflammation and Acute Coronary Syndrome
Condition: Patients With Acute Coronary Syndrome
Intervention: Other: Particulate air pollutants
Outcome Measure: Impact of air pollution on inflammation, oxidative stress and 1-year prognosis in patients hospitalized for Acute Coronary syndrome.
2 Not yet recruiting Integrating Depression Care in Acute Coronary Syndromes Care in China
Conditions: Acute Coronary Syndromes;   Depression
Intervention: Other: integrated care model for Acute Coronary Syndromes (ACS) and depression
Outcome Measures: Changes in mean Patient Health Questionnaire-9 (PHQ-9) score from baseline to 6 months;   Changes in mean PHQ-9 score from baseline to 12 months;   Incidence of Major Adverse Cardiovascular Events (MACE);   Proportion of patients with self-reported adherence to evidence-based Acute Coronary Syndromes (ACS) secondary prevention treatment at 6 and 12 months;   Quality of life at 6 and 12 months after discharge
3 Recruiting Colchicine for Acute Coronary Syndromes
Condition: Acute Coronary Syndrome
Interventions: Drug: Colchicine;   Drug: Placebo
Outcome Measures: Overall mortality, new Acute Coronary syndrome, and ischemic stroke.;   Mortality;   New Acute Coronary syndrome (unstable angina and myocardial infarction);   Ischemic Stroke
4 Not yet recruiting RuSsian RegisTry of Acute Coronary SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy
Condition: Acute Coronary Syndrome
Intervention:
Outcome Measures: Proportion of patients receiving different types of short-term antithrombotic treatment according to different type of Acute Coronary syndrome (STEMI - ST-elevation myocardial infarction, NSTE(Non-ST-elevation)-ACS and Unstable Angina). (Part A);   Proportion of patients taking ticagrelor with cardiovascular (CV) events after discharge from hospital depending on DAT (Dual Antiplatelet Therapy) duration. (Part B);   Proportion of patients who undergo invasive or non-invasive short-term clinical management according to different type of Acute Coronary syndrome (STEMI, NSTE-ACS and Unstable Angina). (Part A);   Time from first symptoms onset to the time of hospitalization (Part A);   Proportion of patients receiving different types of ACS treatment depending on ACS symptoms duration prior hospitalization. (Part A);   Patients demographic and baseline characteristics (age, gender, weight, height). (Part A);   Proportion of patients with different type of coronary intervention strategies. (Part A);   Proportion of patients who is on ticagrelor treatment during 0-3 months, >3-6 months, >6-9 months, >9-12 months. (Part B);   Proportion of patients with ticagrelor treatment interruptions according to different clinical and non-clinical events (bleeds, planned and non-planned medical interventions, etc.) during follow-up. (Part B);   Proportion of patients with thrombo-embolic events during follow-up depending on DAT therapy duration. (Part B);   Proportion of patients who discontinued ticagrelor and reason to discontinue ticagrelor treatment. (Part B);   Proportion of patients with significant violations of treatment regimen with ticagrelor. (Part B);   Start and stop dates of dual antipatelet therapy and ticagrelor (as part of DAT) and duration of exposure to DAT and ticagrelor in real-life setting. (Part B);   Proportion of patients who discontinued DAT and the reason of discontinuation of DAT in real-life setting. (Part B);   Proportion of patients who change DAT components and reason to change of DAT. (Part B);   Proportion of patients with CV-events (recurrent Myocardial Infarction-MI, stroke, ischemia-driven revascularization, death, etc.) in long-term perspective (second year) after index event in real-life setting. (Part B);   Proportion of patients using different type of antithrombotic therapy in long-term perspective (second year) after index event. (Part B);   Proportion of patients who managed by cardiologist, therapist and other physician after discharge from the hospital. (Part B)
5 Unknown  Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome
Condition: Acute Coronary Syndromes
Interventions: Drug: Ivabradine;   Drug: Placebo
Outcome Measures: Whether initiation of ivabradine therapy in patients with Acute Coronary syndromes immediately after hospital admission decreases high-sensitivity C-reactive protein.;   Whether initiation of ivabradine therapy decreases the occurrence of ischemic events (death, nonfatal myocardial infarction, unstable angina, urgent revascularization, cardiac arrest) in patients with Acute Coronary syndromes.
6 Unknown  Quantification and Description of the Increase in Serum Troponin Following Acute Coronary Syndrome
Conditions: Acute Coronary Syndrome;   Myocardial Infarction;   Unstable Angina
Intervention:
Outcome Measure: Evaluation of troponins kinetic in Acute Coronary syndromes.
7 Recruiting Intensive Arterial Pressure Control in Acute Coronary Syndrome
Condition: Acute Coronary Syndrome
Interventions: Drug: Isosorbide Dinitrate;   Drug: Labetalol
Outcome Measures: mortality;   recurrence of chest pain;   Acute Coronary Syndrome complication;   revascularisation;   stroke;   non cardiac deaths
8 Recruiting Acute Coronary Syndrome Genetic Study
Condition: Acute Coronary Syndrome
Intervention:
Outcome Measure: Major adverse cardiovascular events
9 Recruiting Function of High Density Lipoproteins in Acute Coronary Syndromes
Condition: Acute Coronary Syndrome
Intervention:
Outcome Measure: HDL-mediated cellular cholesterol efflux
10 Recruiting Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
Condition: Acute Coronary Syndrome
Intervention:
Outcome Measures: Medical information;   Drug exposure;   Other medical events of interest
11 Not yet recruiting Long-term Follow-up of Health Related Quality of Life in Patients With Acute Coronary Syndrome
Condition: Acute Coronary Syndrome
Intervention:
Outcome Measures: Health related quality of life;   Mortality
12 Unknown  The Correlation Between Genetic Polymorphism, Platelet Activity, Clopidogrel Responsiveness, and Serum Adipokine Concentration in Asian Acute Coronary Syndrome Patients
Conditions: Acute Coronary Syndrome;   Chronic Coronary Artery Disease
Intervention:
Outcome Measure:
13 Recruiting Incidence and Prognostic Value of DELIRIUM in Patients With Acute Coronary synDrome: an observatIonal Study
Conditions: Delirium;   Acute Coronary Syndrome
Intervention:
Outcome Measures: in-hospital adverse events incidence;   12-month adverse events incidence
14 Unknown  Shared Care Rehabilitation After Acute Coronary Syndrome
Conditions: Acute Coronary Syndrome;   Myocardial Ischemia;   Acute Myocardial Infarction: Rehabilitation Phase
Intervention: Behavioral: Shared Care model
Outcome Measures: Participation in cardiac rehabilitation;   Change of BMI and / or abdominal circumference;   24-hour Ambulatory Blood Pressure;   Blood Cholesterol values (Total, LDL, HDL);   Fasting Blood glucose;   Exercise Capacity;   Lifestyle changes;   Depression score;   Compliance to pharmaceutical treatment;   Readmission;   Change in Health Related Quality of Living;   Difference in Health economic costs
15 Unknown  Acute Coronary Syndrome and Care-Seeking Delay: A Web Based Behavioral Study
Conditions: Acute Myocardial Infarction;   Heart Attack;   Acute Coronary Syndrome;   Unstable Angina
Intervention:
Outcome Measure: Decision points and situations and circumstances critical to producing patterns of care-seeking that are efficient and expeditious or are protracted and delayed.
16 Recruiting Clinical Pathways for the Management of Acute Coronary Syndromes - Phase 3,CPACS-3
Condition: Acute Coronary Syndromes
Intervention: Behavioral: quality improvement initiatives
Outcome Measures: incidence rate of in-hospital major adverse cardiovascular events (MACE);   composite score calculated by KPIs of ACS care;   a composite of MACE and re-hospitalization due to cardiovascular disease within 6 months after discharge
17 Recruiting Persistent Platelet Reactivity in Acute Coronary Syndrome
Condition: Acute Coronary Syndrome
Intervention:
Outcome Measures: maximum aggregation intensity;   Maximum aggregation intensity
18 Recruiting Registry of Acute Coronary Syndromes in the Lazio Region of Italy
Condition: Acute Coronary Syndromes
Intervention:
Outcome Measures: Total Mortality;   Cardiovascular Mortality;   New admissions of ACS;   New admissions for heart failure;   New admissions for coronary revascularization
19 Recruiting The LADIES Acute Coronary Syndromes Study
Conditions: Acute Coronary Syndromes;   Menopause
Intervention:
Outcome Measure: Extent of coronary artery disease at angio corelab (Gensini and SYNTAX score)
20 Not yet recruiting PhaRmacodynamic Effect of Therapy With PraSugrel or TicagrElor in Acute Coronary Syndrome paTients With Diabetes Mellitus
Condition: Acute Coronary Syndrome
Interventions: Drug: ticagrelor;   Drug: prasugrel
Outcome Measures: The non-inferiority antiplatelet effect in terms of level platelet reactivity (< 240 PRU) of loading dose of prasugrel (60 mg) versus loading dose of Ticagrelor (180 mg) in patients undergoing PPCI at 6 hours from the administration of the drug.;   Bleeding (major, minor, or minimal according to the TIMI study criteria)

These studies may lead to new treatments and are adding insight into Cefoperazone/sulbactam etiology and treatment.

A major focus of Cefoperazone/sulbactam research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Cefoperazone/sulbactam